NCT04861571Fut, nem toboroz
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
Effect of Very Low-calorie Diet on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and Non-alcoholic Fatty Liver Disease
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. márc. 10.
Rövid összefoglaló (regiszter, angolul)
Non-alcoholic fatty liver disease (NAFLD) is a common complication of obesity which can progress to deadly complications like end-stage liver disease and hepatocellular carcinoma. In the wake of the obesity epidemic, NAFLD is becoming the main etiology of liver transplantation in the US. Currently, there are no FDA approved pharmacological treatments for NAFLD. Weight loss through lifestyle modifications, pharmacotherapy and bariatric surgery can be effective strategies for the management of NAFLD. Even though substantial weight loss and improvement in NAFLD can be achieved with bariatric surgery, only a small proportion of patients with obesity undergo surgery. Very-low calorie diets (VLCD) are replacement meals manufactured to substitute natural foods and limited total intake of 800-960 kcal in divided meals. Very low-calorie diets can produce substantial weight loss of 10% over 2 to 3 months. We hypothesize that VLCD reduce liver steatosis and, fibrosis measured non-invasively with transient elastography. Our main aim is #1 to assess the effect of VLCD on liver fatty infiltration and fibrosis. We also have three exploratory aims exploring novel pathogenic factors that mediate the improvement of NAFLD by VLCD: #2 assess the effect of VLCD on micro RNAs (miRs) associated with pathophysiology of NAFLD: #3 assess the effect of VLCD on changes of salivary and fecal microbiome in the setting of NAFLD: #4 to determine the effect of VLCD on platelet function. This pilot project will produce preliminary data for the development of a larger grant application to study the efficacy of VLCD in the management of NAFLD. Furthermore, it will potentially identify factors that mediate improvement of NAFLD after VLCD. We will treat 10 subjects with obesity and NAFLD for 8 weeks with VLCD or lower calorie diet (control group) and obtain transient elastography before and after the interventions along with other measurements of interest. Our project may have significant impact by establishing VLCD as a clinically effective option for the improvement of liver steatosis and fibrosis in patients with obesity and NAFLD ineligible or without access to bariatric surgery.
- Állapot (regiszter)
- Fut, nem toboroz
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 20 (tervezett)
- Első benyújtás
- 2021. ápr. 21.
- Kezdés
- 2023. okt. 1.
- Elsődleges befejezés
- 2026. júl.
- Fő szponzor
- University of Iowa
- Betegségek
- Elhízás, Zsírmáj (MASLD/MASH)
- NCT-szám
- NCT04861571
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Tervezett résztvevők: 20
- 2023. okt. 1. és az elsődleges befejezés (2026. júl.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
A regiszterben nem jelölt feltételek
- Inclusion and Exclusion Criteria
- The inclusion criteria for participation are as follows:
- Male and female subjects with age ≥ 18 years old and < 70 years old.
- BMI ≥ 30 kg/m2 and ≤ 50 kg/m2
- Negative tests for viral hepatitis C (hepatitis C antibody) and autoimmune hepatitis (anti-smooth muscle antibody)
- Evidence of liver steatosis on an image method such as ultrasound, CT scan or MRI, or subjects with elastography score F1 and above and/or S1 and above can be included
- The exclusion criteria are as follows:
- Type 1 diabetes mellitus
- Subjects with type 2 diabetes mellitus who use insulin
- Heart failure
- Myocardial infarction within last 6 months
- Unstable angina
- Chronic kidney disease with eGFR ≤ 30 mL/min/1.73 m²
- Chronic obstructive pulmonary disease requiring O2 supplementation
- Coexisting liver disease or end-stage liver disease
- Severe or uncontrolled mental health disease, including eating disorders
- Gout
- History of uric acid nephrolithiasis
- Porphyria
- Conception attempts, confirmed pregnancy or breast feeding
- Past or active cholecystitis without cholecystectomy
- Uncontrolled hyperthyroidism
- Uncontrolled hypothyroidism with TSH ≥ 10 mcIU/mL
- Excessive alcohol consumption (that is, an AUDIT-C score ≥ 4 for men and ≥ 3 for women)
- Use of warfarin, lithium, chronic use of prednisone (20mg or more daily)
- Subjects with no elastography in the previous 12 months will be excluded from the study
- Subjects with F0 and S0 on elastography will be excluded
Életkor a regiszterben: 18 év – 70 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| University of Iowa Health Care | Iowa City | Egyesült Államok | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.